Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Eli Lilly and reads as neutral right now, with no clear lean either way.
- What's working
- Its price has held up well, trading above its recent averages.
- Worth watching
- You're paying more for it than for most other healthcare companies, relative to what it earns.
Analyst price target
~12-month · 30 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 50,000
- Headquarters
- Indianapolis, IN
Similar stocks
What’s behind the score
Valuation
P/E 42.2 — lower than 18% of Healthcare peers
P/B 33.1 — lower than 0% of Healthcare peers
P/S 14.1 — lower than 3% of Healthcare peers
EV/EBITDA 28.0 — lower than 3% of Healthcare peers
EV/Revenue 14.6 — lower than 3% of Healthcare peers
PEG 1.2 — lower than 67% of Healthcare peers
FCF yield 1.0% — higher than 7% of Healthcare peers
Profitability & quality
Gross margin 83.4% — higher than 100% of Healthcare peers
Operating margin 54.2% — higher than 100% of Healthcare peers
Net margin 33.5% — higher than 97% of Healthcare peers
ROE 102.3% — higher than 100% of Healthcare peers
ROA 20.4% — higher than 97% of Healthcare peers
Free cash flow is 41% of reported net income
Financial health
Debt/equity 1.6 — lower than 11% of Healthcare peers
Current ratio 1.35 — higher than 41% of Healthcare peers
Quick ratio 0.68 — higher than 21% of Healthcare peers
Cash/debt 0.16 — higher than 34% of Healthcare peers
Debt/EBITDA 1.32 — lower than 76% of Healthcare peers
Growth
Revenue growth 47.7% YoY — higher than 100% of Healthcare peers
Earnings growth 26.2% YoY — higher than 54% of Healthcare peers
Ownership & investor activity
Payout ratio 21.7% — typical for Healthcare peers
Net insider selling, -18.0% of insider shares
Institutions net sold, -10.4% of shares held
Insiders hold 0.2% of shares outstanding
0.8% of float sold short
Momentum
Above its 50- & 200-day averages
93% of the way from its 52-week low to high